Received Mar 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | 4 | U7899AA | IM / RL |
| FLU4 | INFLUENZA (SEASONAL) (FLUARIX QUADRIVALENT) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 72RF2 | IM / LL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y017208 | SC / RL |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 4 | LC5483 | IM / LL |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y017208 | OT / RL |
No adverse effects reported; received improperly stored PROQUAD; This spontaneous report was received from a nurse referring to a 3-year-old female patient. Concurrent condition and medical history were not reported. Concomitant vaccines included Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine (VAXELIS), Pneumococcal vaccine conj 20v (CRM197) (PREVNAR 20), and Influenza vaccine inact split 4v (FLUARIX QUADRIVALENT). On 01-OCT-2024, the facility received a shipment of COIVD vaccine that needed to be stored in the freezer. There was no room in the freezer to accommodate the shipment. On 05-FEB-2025, the patient was vaccinated with the first dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) lyophilisate and solvent for solution for injection, administered subcutaneously in the right thigh for prophylaxis at public health clinic (lot# Y017208 has been verified to be a valid lot number, expiration date not reported, but upon internal validation established as 13-APR-2026; strength and dose were not reported). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (strength, lot#, and expiration date were not reported). It was assumed that the vaccine could be refrigerated and was moved to the refrigerators where they remained within normal refrigerated temperature range (36 to 46 degree Fahrenheit) until administration. The vaccine arrived at the facility on 13-OCT-2025 and was refrigerated until administration (Product storage error). No adverse effects were reported. This is one of several reports received from the same reporter.
Vaxelis; Prevnar 20; Fluarix Quadrivalent; sterile diluent